Research and Development Costs (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 10 Months Ended |
|---|---|---|---|---|
Mar. 25, 2021 |
Jun. 30, 2021 |
Jun. 30, 2021 |
Jun. 30, 2021 |
|
| Research and Development Costs | ||||
| Grant income | $ 400,000 | $ 400,000 | $ 400,000 | |
| Obligations related payment | $ 200,000 | 100,000 | ||
| Cumulative amount | $ 200,000 | |||
| Total Project value | $ 663,000 | $ 846,000 |
| X | ||||||||||
- Definition Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for awa No definition available.
|
| X | ||||||||||
- Definition The amount of retained obligations related to divested businesses included in liabilities subject to compromise. No definition available.
|
| X | ||||||||||
- Definition The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do No definition available.
|
| X | ||||||||||
- Definition Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|